Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody

[1]  J. Parisi,et al.  Multi-organ reactivity of a monoclonal natural autoantibody that promotes remyelination in a mouse model of multiple sclerosis. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  K. Asakura,et al.  Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes , 1996, Journal of neuroscience research.

[3]  M. Rodriguez,et al.  A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. , 1996, International immunology.

[4]  M. Samson,et al.  Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. , 1995, Journal of immunology.

[5]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[6]  K. Asakura,et al.  Experimental strategies to promote central nervous system remyelination in multiple sclerosis: Insights gained from the Theiler's virus model system , 1995, Journal of neuroscience research.

[7]  M. Pappolla,et al.  Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis , 1995, Journal of Neuroimmunology.

[8]  M. Rodriguez,et al.  A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. , 1995, Journal of immunology.

[9]  K. Selmaj,et al.  Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I , 1995, Journal of Neuroimmunology.

[10]  M. Rodriguez,et al.  Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  A. Coutinho,et al.  Observations on the Mode of Action of Normal Immunoglobulin at High Doses , 1994, Immunological reviews.

[12]  I. Cohen,et al.  Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. , 1994, The Journal of clinical investigation.

[13]  T. Ternynck,et al.  The natural autoantibodies system: between hypotheses and facts. , 1993, Molecular immunology.

[14]  D. McFarlin,et al.  Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2 , 1993, Journal of Neuroimmunology.

[15]  A. Weinberg,et al.  Treatment of relapsing experimental autoimmune encephalomyelitis with T cell receptor peptides , 1993, Journal of neuroscience research.

[16]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[17]  C. Gordon,et al.  Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. , 1992 .

[18]  F. Barkhof,et al.  Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis , 1992, Annals of neurology.

[19]  S. Kaveri,et al.  Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. , 1992, Clinical immunology and immunopathology.

[20]  S. Miller,et al.  Specific Immunoregulation of the Induction and Effector Stages of Relapsing EAE via Neuroantigen‐Specific Tolerance Induction , 1991, Annals of the New York Academy of Sciences.

[21]  S. Sriram,et al.  Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91–103 of myelin basic protein , 1991, Journal of Neuroimmunology.

[22]  D. Holmberg,et al.  Monoclonal, natural antibodies prevent development of diabetes in the non-obese diabetic (NOD) mouse. , 1991, Journal of autoimmunity.

[23]  P. Albert,et al.  Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. , 1991, Journal of immunology.

[24]  L. Steinman,et al.  The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. , 1991, Advances in immunology.

[25]  A. Coutinho,et al.  Suppression of antibody responses to the acetylcholine receptor by natural antibodies , 1989, European journal of immunology.

[26]  H. Mcdevitt,et al.  Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention , 1988, Cell.

[27]  I. Cohen,et al.  Natural autoantibodies might prevent autoimmune disease. , 1986, Immunology today.

[28]  S. Sriram,et al.  Treatment of established chronic relapsing experimental allergic encephalomyelitis with anti-L3T4 antibodies. , 1986, Journal of immunology.

[29]  Moses Rodriguez,et al.  Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region , 1986, The Journal of experimental medicine.

[30]  L. Steinman,et al.  Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes , 1983, The Journal of experimental medicine.

[31]  E. Schuller,et al.  First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. , 1983, European neurology.